Alnylam Pharmaceuticals
ALNY
224.41
+0.47
+0.21%
Alnylam Pharmaceuticals
US · ALNY
#627 by market cap
Listed 1970
224.41
+0.47
+0.21%
Live - 5344 symbols - heartbeat 66s ago
· 2026-10-08 06:06
Pre-market
224.50
+0.04%
After-hours
224.41
0.00%
Overnight
224.32
-0.04%
- Market cap
- 30.03B
- P/E (TTM)i
- 39.10
- P/Bi
- 22.17
- EPSi
- 2.33
- Div yieldi
- 0.00%
- 52W posi
- 9%
Reader sentiment
Are you bullish or bearish on ALNY?
Anonymous reader poll. Unscientific, not investment advice.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel, and Phillip Allen Sharp on June 14, 2002, and is headquartered in Cambridge, MA.
- Founded
- 2002
- CEO
- Dr. Yvonne L Greenstreet, MB.Ch.B.
- Employees
- 2,500
- Headquarters
- Cambridge, Massachusetts, United States of America
- Fiscal year end
- 12-31
- Website
- alnylam.com
Company profile
- Exchange
- US
- Symbol
- ALNY
- Market-cap rank
- #627
- Listing date
- 1970-01-01
- Market cap
- 30.03B
- Float cap
- 29.90B
- Shares out
- 133.81M
- Float shares
- 133.24M
Sectors & themes
Biotechnology
Fractional Shares JP
Quote time 2026-10-08 06:06:04 · For reference only, not investment advice and not tailored to your situation.